ArticleeLife2020
eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Mapping the functional dark proteome in cancer.Nature reviews. Cancer · 2026Review
- N7-Methylguanosine Modification in Colorectal Cancer: Molecular Insights and Clinical Implications.International journal of molecular sciences · 2026Review
- Article
- Reactivating necroptosis in colorectal cancer potentiates chemotherapy and antitumor immune responses.Cancer letters · 2026Article
- The many ways to inhibit translation by Sorafenib in liver cancer cells.Molecular and cellular biochemistry · 2026Article
- RNA-binding proteins as therapeutic targets in cancer.RNA biology · 2025Review
- Article
- PPM1G dephosphorylates eIF4E in control of mRNA translation and cell proliferation.Life science alliance · 2024Article
- GRP78 inhibitor YUM70 upregulates 4E-BP1 and suppresses c-MYC expression and viability of oncogenic c-MYC tumors.Neoplasia (New York, N.Y.) · 2024Article
- miR-483-5p orchestrates the initiation of protein synthesis by facilitating the decrease in phosphorylated Ser209eIF4E and 4E-BP1 levels.Scientific reports · 2024Article
- Molecular interaction and MD-simulations: investigation of Sizofiran as a promising anti-cancer agent targeting eIF4E in colorectal cancer.In silico pharmacology · 2024Article
- Targeting Myc-driven stress addiction in colorectal cancer.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2023Review
- Article
- Proteomic screening identifies RPLp2 as a specific regulator for the translation of coronavirus.International journal of biological macromolecules · 2023Article
- Translational regulation of cell invasion through extracellular matrix-an emerging role for ribosomes.F1000Research · 2023Review
- Biological functions and research progress of eIF4E.Frontiers in oncology · 2023Review
- Article
- Targeting GRP78 suppresses oncogenic KRAS protein expression and reduces viability of cancer cells bearing various KRAS mutations.Neoplasia (New York, N.Y.) · 2022Article
- A noncanonical function of EIF4E limits ALDH1B1 activity and increases susceptibility to ferroptosis.Nature communications · 2022Article
- Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer.Molecular biomedicine · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 3 institutions in 3 countries.
Hang Ruan *Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, United States.
Xiangyun Li *Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, United States.
Xiang XuDepartment of Stem cell and regenerative medicine, Daping Hospital, Army Medical University, Chongqing, China.
Brian J LeibowitzDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, United States.
Jingshan TongUPMC Hillman Cancer Center, Pittsburgh, United States.
Lujia ChenUPMC Hillman Cancer Center, Pittsburgh, United States.
Luoquan AoDepartment of Stem cell and regenerative medicine, Daping Hospital, Army Medical University, Chongqing, China.
Wei XingDepartment of Stem cell and regenerative medicine, Daping Hospital, Army Medical University, Chongqing, China.
Jianhua LuoDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, United States.
Yanping YuDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, United States.
Robert E SchoenDepartments of Medicine and Epidemiology, University of Pittsburgh, Pittsburgh, United States.
Nahum SonenbergDepartment of Biochemistry, Goodman Cancer Research Centre, McGill University, Montreal, Canada.ORCID http://orcid.org/0000-0002-4707-8759
Xinghua LuUPMC Hillman Cancer Center, Pittsburgh, United States.ORCID http://orcid.org/0000-0002-8599-2269
Lin ZhangUPMC Hillman Cancer Center, Pittsburgh, United States.
Jian YuDepartment of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, United States.ORCID https://orcid.org/0000-0002-4021-1000
University of Pittsburgh · USArmy Medical University · CNMcGill University Health Centre · CA
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MInterpretable deep learning models for translational medicine RenewalR01LM012011 · NLM · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Tanner J. Freeman, XINGHUA LU · 2015 to 2026
$3.6MTranslation addiction and targeting in colon cancerR01CA215481 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YU, JIAN · 2018 to 2022
$2.3MRole of necroptosis in colorectal cancer therapyR01CA236271 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZHANG, LIN · 2019 to 2023
$2.2MRole of Mcl-1 degradation in colorecal cancer therapyR01CA203028 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, LIN · 2016 to 2020
$1.7MBid-mediated killing of oncogenic stem cells in chemopreventionR01CA172136 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, LIN · 2013 to 2017
$1.6MNational Key R and D Program of China 2018YFC1313400NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA172136NCI NIH HHS R01 CA203028NCI NIH HHS R01 CA215481NIH HHS R01CA236271NLM NIH HHS R01 LM012011
Abstract
To better understand a role of eIF4E S209 in oncogenic translation, we generated
Indexed as
Activating Transcription Factor 4Adenomatous Polyposis Coli ProteinAnimalsCarcinogenesisCell DeathCell Line, TumorCell ProliferationCell SurvivalEukaryotic Initiation Factor-4EFemaleHumansMiceMice, NudeNeoplasms, ExperimentalPhosphorylationProto-Oncogene Proteins c-mycActivating Transcription Factor 4Adenomatous Polyposis Coli Proteinadenomatous polyposis coli protein, mouseATF4 protein, humanEukaryotic Initiation Factor-4EKRAS protein, humanMYC protein, humanProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)cancer biologycolon cancereIF4E S209glutaminehumanKRASmouseMycthe integrated stress response
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.